Failure of carbazochrome sodium sulfonate (AC-17) to prevent Dengue vascular permeability or shock: A randomized, controlled trial
Failure of carbazochrome sodium sulfonate (AC-17) to prevent Dengue vascular permeability or shock: A randomized, controlled trial
复制标题
DOI：
10.1016/s0022-3476(97)70055-6
复制
发表时间：
1997-10-01
影响因子：
5.1
通讯作者：
Chirawatkul, A
中科院分区：
文献类型：
--
作者：
Tassniyom, S;Vasanawathana, S;Chirawatkul, A
目的：我们研究了卡络磺钠（AC-17），以防止毛细血管通透性在登革出血热/登革休克syndrome.Method：一个随机的，安慰剂对照试验，在95名儿童分层的年龄和性别在1992年期间在两家医院进行。AC-17（n = 45例）或B族维生素作为安慰剂（n = 50），给予推注，然后作为连续滴注24 h;共300 mg的AC-17的前2天和150 mg的第3 d.Results：两组在年龄，性别，病程，临床表现是可比的。两组间休克或胸腔积液无显著差异。AC-17组8.9%（4/45）的患者和安慰剂组6%（3/50）的患者发生休克（p = 0.44）。AC-17组在入院后0、24、48和72小时分别有4.4%、20%、31.1%和20%的患者出现胸腔积液，安慰剂组分别有2%、14%、28%和14%.Conclusion：AC-17不能预防登革出血热/登革休克综合征患者的血浆渗漏或休克。
Objective: We studied the ability of carbazochrome sodium sulfonate (AC-17) to prevent capillary permeability in dengue hemorrhagic fever/dengue shock syndrome.Method: A randomized, placebo-controlled trial in 95 children stratified by age and sex was conducted in two hospitals during 1992. AC-17 (n = 45 cases) or B vitamins as placebo (n = 50) were given as a bolus infusion and then as a continuous drip for 24 hours; a total of 300 mg of AC-17 was administered on the first 2 days and 150 mg on the third day.Results: The two groups were comparable in age, sex, duration of illness, and clinical manifestations. No significant difference in shock or pleural effusion was noted between the two groups. Shock developed in 8.9% (4/45) of patients in the AC-17 group and 6% (3/50) in the placebo group (p = 0.44). Pleural effusion was found at 0, 24, 48, and 72 hours after admission in 4.4%, 20%, 31.1%, and 20% in the AC-17 group and 2%, 14%, 28%, and 14% in the placebo group, respectively.Conclusion: Administration of AC-17 does not prevent plasma leakage or shock in dengue hemorrhagic fever/dengue shock syndrome.